As previously reported, Cantor Fitzgerald downgraded Tvardi Therapeutics (TVRD) to Neutral from Overweight after the company provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. Given what the firm calls “breathtakingly negative data,” it sees “no path forward in IPF” and based on the “poor” tolerability and “exceedingly high” discontinuation rates, it has “limited hope” for the ongoing HCC study as well, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVRD:
- Tvardi Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Tvardi Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Morning Movers: Bloom Energy surges following $5B investment from Brookfield
- Why Is Tvardi Therapeutics Stock (TVRD) Down 85% Today?
- Tvardi says benefit of TTI-101 treatment not observed in REVERT trial